FDA Approves STELARA — Janssen Biotech, Inc.

On September 25, 2009, Janssen Biotech, Inc. received FDA approval for Ustekinumab (Stelara), a monoclonal antibody scheduled to generate substantial revenue in the lucrative autoimmune market. This approval signals a critical expansion for Janssen’s therapeutic pipeline as it targets psoriasis and Crohn's disease, solidifying its competitive standing against rivals AbbVie and Johnson & Johnson.